Home Alzheimer’s Disease FDA Approves Ibrutinib Combined with Rituximab for Patients with CLL/SLL

FDA Approves Ibrutinib Combined with Rituximab for Patients with CLL/SLL

The FDA expanded the indication of ibrutinib (Imbruvica) to include its combination with rituximab (Rituxan) for the initial treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).1

The review was conducted under Project Orbis, and the FDA is collaborating with the Australian Therapeutic Goods Administration, Health Canada, and Swissmedic as they continue to review the application.

The approval was based on the phase III E1912 trial, which was a multicenter, open-label, activity-controlled trial which randomized patients in a 2:1 fashion to either ibrutinib with rituximab or a combination of fludarabine (Fludara), cyclophosphamide, and rituximab (FCR). The primary endpoint for the trial was progression-free survival (PFS), and one of the secondary endpoints was overall survival (OS).2

The primary study results were published in The New…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Cause of Alzheimer’s disease traced to mutation in common enzyme

submitted by /u/scotsman81 Continue Reading to the Source

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Patients, Family & Friends, and Healthcare professionals : braincancer

I am currently a PhD student based at the Marie Curie Palliative Care Research Centre at Cardiff University. My PhD is focussed on developing...

Recent Comments